Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI
Vancouver, Canada, July 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering non‑hallucinogenic neuroplastogen‑derived treatments for Alcohol Use Disorder (AUD), addiction, and weight management, announced today compelling ex vivo mucoadhesion results for its intranasal formulation of MEAI (5‑Methoxy‑2‑aminoindane). Leveraging a nasal drug‑delivery system, the new formulation demonstrated markedly improved nasal residence chara
Vancouver, Canada, July 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering non‑hallucinogenic neuroplastogen‑derived treatments for Alcohol Use Disorder (AUD), addiction, and weight management, announced today compelling ex vivo mucoadhesion results for its intranasal formulation of MEAI (5‑Methoxy‑2‑aminoindane). Leveraging a nasal drug‑delivery system, the new formulation demonstrated markedly improved nasal residence characteristics compared with a standard MEAI solution.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.